title: Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV).
abstract: Metals of interest for biomedical applications often need to be complexed and associated in a stable manner with a targeting agent before use. Whereas the fundamentals of most transition-metal complexation processes have been thoroughly studied, the complexation of Zr(IV) has been somewhat neglected. This metal has received growing attention in recent years, especially in nuclear medicine, with the use of (89) Zr, which a β(+) -emitter with near ideal characteristics for cancer imaging. However, the best chelating agent known for this radionuclide is the trishydroxamate desferrioxamine B (DFB), the Zr(IV) complex of which exhibits suboptimal stability, resulting in the progressive release of (89) Zr in vivo. Based on a recent report demonstrating the higher thermodynamic stability of the tetrahydroxamate complexes of Zr(IV) compared with the trishydroxamate complexes analogues to DFB, we designed a series of tetrahydroxamic acids of varying geometries for improved complexation of this metal. Three macrocycles differing in their cavity size (28 to 36-membered rings) were synthesized by using a ring-closing metathesis strategy, as well as their acyclic analogues. A solution study with (89) Zr showed the complexation to be more effective with increasing cavity size. Evaluation of the kinetic inertness of these new complexes in ethylenediaminetetraacetic acid (EDTA) solution showed significantly improved stabilities of the larger chelates compared with (89) Zr-DFB, whereas the smaller complexes suffered from insufficient stabilities. These results were rationalized by a quantum chemical study. The lower stability of the smaller chelates was attributed to ring strain, whereas the better stability of the larger cyclic complexes was explained by the macrocyclic effect and by the structural rigidity. Overall, these new chelating agents open new perspectives for the safe and efficient use of (89) Zr in nuclear imaging, with the best chelators providing dramatically improved stabilities compared with the reference DFB.
authors.affiliation: Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 (USA), Fax: (+1) 301-402-1923. francois.guerard@univ-nantes.fr.
authors.forename: François
authors.initials: F
authors.lastname: Guérard
authors.forename: Yong-Sok
authors.initials: YS
authors.lastname: Lee
authors.forename: Martin W
authors.initials: MW
authors.lastname: Brechbiel
mesh_terms: D002614:Chelating Agents / Q000737:chemistry*; D056831:Coordination Complexes / Q000737:chemistry*; D018360:Crystallography, X-Ray; D003676:Deferoxamine / Q000737:chemistry*; D004492:Edetic Acid / Q000737:chemistry*; D005290:Ferric Compounds / Q000737:chemistry*; D006877:Hydroxamic Acids / Q000138:chemical synthesis* / Q000737:chemistry; D007700:Kinetics; D049268:Positron-Emission Tomography; D011868:Radioisotopes / Q000737:chemistry*; D015040:Zirconium / Q000737:chemistry*
chemical_list: D002614:Chelating Agents; D056831:Coordination Complexes; D005290:Ferric Compounds; D006877:Hydroxamic Acids; D011868:Radioisotopes; C002577:ferrioxamine B; D004492:Edetic Acid; D015040:Zirconium; D003676:Deferoxamine
keywords: chelates; imaging agents; ligand design; quantum chemistry; zirconium
references.citation: Bioconjug Chem. 2009 May 20;20(5):825-41
references.pmid: 19125647
references.citation: Chem Rev. 2010 May 12;110(5):2858-902
references.pmid: 20415480
references.citation: Bioconjug Chem. 2011 Oct 19;22(10):2048-59
references.pmid: 21877749
references.citation: Nucl Med Biol. 2011 Jul;38(5):675-81
references.pmid: 21718943
references.citation: Adv Drug Deliv Rev. 2010 Aug 30;62(11):1031-51
references.pmid: 20854860
references.citation: Nucl Med Biol. 2009 Oct;36(7):729-39
references.pmid: 19720285
references.citation: Bioconjug Chem. 2001 Jan-Feb;12(1):7-34
references.pmid: 11170362
references.citation: Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9
references.pmid: 19763566
references.citation: Nat Protoc. 2010 Apr;5(4):739-43
references.pmid: 20360768
references.citation: Dalton Trans. 2014 Jan 7;43(1):119-31
references.pmid: 24104523
references.citation: J Chem Phys. 2006 Nov 21;125(19):194101
references.pmid: 17129083
references.citation: Molecules. 2013 Jun 03;18(6):6469-90
references.pmid: 23736785
references.citation: Adv Drug Deliv Rev. 2013 Jul;65(8):1098-111
references.pmid: 23123291
references.citation: J Nucl Med. 2012 Jan;53(1):113-20
references.pmid: 22213822
references.citation: Nucl Med Biol. 2013 Jan;40(1):3-14
references.pmid: 22998840
references.citation: Angew Chem Int Ed Engl. 2012 Nov 12;51(46):11426-37
references.pmid: 23086547
references.citation: Angew Chem Int Ed Engl. 2000 Apr;39(8):1442-1444
references.pmid: 10777635
references.citation: Nucl Med Biol. 2010 Apr;37(3):289-97
references.pmid: 20346868
references.citation: Nat Med. 2012 Oct;18(10):1586-91
references.pmid: 23001181
references.citation: Chem Commun (Camb). 2013 Feb 1;49(10):1002-4
references.pmid: 23250287